Tags

Type your tag names separated by a space and hit enter

JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results.
J Neurol Sci 2019; 406:116426JN

Abstract

OBJECTIVE

To confirm anti-JC virus (JCV) antibody seroprevalence in Portuguese patients with relapsing-remitting multiple sclerosis (RRMS) and to determine their anti-JCV antibody index.

METHODS

JUSTIFY was a retrospective, multicentre study that included 655 RRMS patients tested at least once with the anti-JCV antibody assay STRATIFY JCV DxSelect. Demographic data, multiple sclerosis history and results of the anti-JCV antibody test were collected, along with physicians' reasons for requesting the test and the impact of the results.

RESULTS

Overall anti-JCV antibody seroprevalence was 60.8% (95% confidence interval, 56.9-64.5). Seroprevalence was associated with higher age (P = .030) and was lower in natalizumab-treated patients (P < .001). The mean anti-JCV antibody index of immunosuppressant-naive patients was 1.5 ± 1.3 (n = 378). The main reasons for performing the test were clinical characterization (35.5%) and medication change (26.2%). In patients who switched treatments (n = 109), fingolimod (47.7%) and natalizumab (26.6%) were the most commonly chosen new treatments.

CONCLUSIONS

The study confirmed the high anti-JCV antibody prevalence in Portuguese RRMS patients and its association with age. These data can be used to better understand the benefit-risk profile of natalizumab treatment in Portuguese patients and to support progressive multifocal leukoencephalopathy risk management strategies.

Authors+Show Affiliations

Centro Hospitalar de São João, Hospital de São João, Department of Neurology, Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal. Electronic address: mjsa@med.up.pt.Centro Hospitalar e Universitário de Coimbra, Hospitais da Universidade de Coimbra, Department of Neurology, Coimbra, Portugal.Centro Hospitalar do Porto, Hospital de Santo António, Department of Neurology, Instituto Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.Biogen, Lisbon, Portugal.Centro Hospitalar de Setúbal, Hospital de São Bernardo, Department of Neurology, Setubal, Portugal.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31629287

Citation

Sá, Maria José, et al. "JC Virus Antibodies in Portuguese Multiple Sclerosis Patients: JUSTIFY Study Results." Journal of the Neurological Sciences, vol. 406, 2019, p. 116426.
Sá MJ, Nunes CC, da Silva AM, et al. JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results. J Neurol Sci. 2019;406:116426.
Sá, M. J., Nunes, C. C., da Silva, A. M., Mota, P., & Pinto-Marques, J. (2019). JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results. Journal of the Neurological Sciences, 406, p. 116426. doi:10.1016/j.jns.2019.116426.
Sá MJ, et al. JC Virus Antibodies in Portuguese Multiple Sclerosis Patients: JUSTIFY Study Results. J Neurol Sci. 2019 Nov 15;406:116426. PubMed PMID: 31629287.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results. AU - Sá,Maria José, AU - Nunes,Carla Cecília, AU - da Silva,Ana Martins, AU - Mota,Patrícia, AU - Pinto-Marques,José, AU - ,, Y1 - 2019/08/13/ PY - 2019/03/11/received PY - 2019/08/02/revised PY - 2019/08/12/accepted PY - 2019/10/20/pubmed PY - 2019/10/20/medline PY - 2019/10/20/entrez KW - Anti-JCV antibody KW - JC virus KW - Multiple sclerosis KW - Natalizumab KW - Progressive multifocal leukoencephalopathy SP - 116426 EP - 116426 JF - Journal of the neurological sciences JO - J. Neurol. Sci. VL - 406 N2 - OBJECTIVE: To confirm anti-JC virus (JCV) antibody seroprevalence in Portuguese patients with relapsing-remitting multiple sclerosis (RRMS) and to determine their anti-JCV antibody index. METHODS: JUSTIFY was a retrospective, multicentre study that included 655 RRMS patients tested at least once with the anti-JCV antibody assay STRATIFY JCV DxSelect. Demographic data, multiple sclerosis history and results of the anti-JCV antibody test were collected, along with physicians' reasons for requesting the test and the impact of the results. RESULTS: Overall anti-JCV antibody seroprevalence was 60.8% (95% confidence interval, 56.9-64.5). Seroprevalence was associated with higher age (P = .030) and was lower in natalizumab-treated patients (P < .001). The mean anti-JCV antibody index of immunosuppressant-naive patients was 1.5 ± 1.3 (n = 378). The main reasons for performing the test were clinical characterization (35.5%) and medication change (26.2%). In patients who switched treatments (n = 109), fingolimod (47.7%) and natalizumab (26.6%) were the most commonly chosen new treatments. CONCLUSIONS: The study confirmed the high anti-JCV antibody prevalence in Portuguese RRMS patients and its association with age. These data can be used to better understand the benefit-risk profile of natalizumab treatment in Portuguese patients and to support progressive multifocal leukoencephalopathy risk management strategies. SN - 1878-5883 UR - https://www.unboundmedicine.com/medline/citation/31629287/JC_virus_antibodies_in_Portuguese_multiple_sclerosis_patients:_JUSTIFY_study_results L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-510X(19)30358-2 DB - PRIME DP - Unbound Medicine ER -